This page provides comprehensive access to Graco Inc. (GGG) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event disclosures (8-K), and insider trading forms. It highlights how investors can use these documents for detailed financial performance and governance insights, enhanced by AI-powered summaries. Recent filings include executive stock option grants, a director's resignation, and insider stock transactions.

Forum Energy Technologies (NYSE:FET) has moved above a key long-term moving average in the NYSE Composite, indicating a significant change in its trading activity. The company provides engineered equipment and services for the global oil and gas exploration and production industry. The article from Kalkine Media focuses on this recent market movement.

This article compiles various trading ideas and analyses for Bank of America Corporation's depositary shares (BAC/PO Series NN) from different traders on TradingView. The perspectives range from bullish long positions based on support levels and ascending triangles to bearish short positions due to resistance levels or channel breakdowns, with some analysts also suggesting a "hold" strategy. It highlights diverse technical and fundamental viewpoints on BAC's potential movements in the near future.

Short interest in the First Trust Small Cap Value AlphaDEX Fund (NASDAQ: FYT) surged by 1,225.4% in March, reaching 19,854 shares. Despite this, several institutional investors, including Blueprint Investment Partners, Jones Financial, and Wells Fargo, increased their stakes in the fund. The fund recently paid a quarterly dividend of $0.2014 and traded down 0.7% to $63.98, with a market cap of approximately $160 million.

Insider Charles Lynn Hamilton sold a total of 774,090 shares of Fermi stock across two transactions on April 8th and 9th, generating over $3.6 million and reducing his stake by nearly 6%. Other insiders also executed significant sales during the same period. Despite a consensus "Buy" rating from analysts with an average price target of $26.89, Fermi's stock is trading at $4.87, and several firms have recently downgraded the stock or cut their price targets, indicating mixed sentiment.

Short interest in the First Trust Emerging Markets AlphaDEX Fund (NASDAQ:FEM) significantly increased by 790.7% as of March 31st, reaching 864,569 shares. This represents about 4.0% of the stock's shares shorted, with a days-to-cover ratio of 4.2 days. The fund recently traded at $32.12, has a market cap of $697 million, and has seen various institutional investors adjust their positions.

A Wirecutter tester shares their surprisingly positive experience shopping for clothing at Costco, detailing items they liked and those they wouldn't recommend. Comments from readers reinforce the idea that Costco can be a good source for basic clothing items, with some even finding designer brands at bargain prices.

Williams-Sonoma promoted Aujsha Taylor to President of Rejuvenation after her significant success in growing the brand's revenue and physical presence. This move, along with other brand collaborations, highlights Williams-Sonoma's strategy to rely on proven leadership and unique concepts to maintain its strong position in upscale home furnishings. While Taylor's promotion supports the consensus for steady growth, investors should consider both the positive impact of such strategic leadership on future earnings and the differing opinions among analysts regarding revenue projections.

Lennox International (LII) is set to report its first-quarter 2026 earnings on April 29, generating investor interest due to its strong financial position and inclusion in a quality investing screen. While the company's robust free cash flow and consistent growth highlight a bullish outlook, investors are also considering potential risks from residential demand softness and elevated cost pressures. The upcoming earnings call will be crucial for clarifying margin resilience.

Replimune is implementing job cuts after the FDA rejected its drug candidate, RP1, for a second time. This development is part of a broader "Finance Watch" update which also covers Cyclerion, Kezar, and IO Biotech exploring strategic alternatives. The recurring FDA rejection for RP1 highlights potential challenges for accelerated approvals within the industry.